Express Mail Label No.: EV 138529515US
Date of Deposit: January 19, 2005 Attorney Docket No.: 22596-538

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Li, et al.

SERIAL NUMBER:

10/726,467

EXAMINER:

Not Yet Assigned

FILING DATE:

December 2, 2003

ART UNIT:

1614

For:

METHOD OF TREATING CANCERS

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT:

Li, et al. 10/726,467

U.S.S.N.:

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 22596-538.

Respectfully submitted,

Havro Reg No 50,572 Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000

Fax: (617) 542-2241

Date: January 19, 2005

TRA 1997589v1

Express Mail Label: EV 138529515 US
Date of Deposit: January 19, 2005

Page 1 of 1 Attorney Docket No.: 22596-538

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)						Application Number	10/726,467			
						Filing Date	December 2, 2003			
						First Named Inventor	Li 1614 Not Yet Assigned			
						Group Art Unit				
						Examiner Name				
						Attorney Docket Number	22596-538			
					U	S. PATENT DOCUMENTS				
Exam Initials				Issue Date		Name of Patentee(s) or Applicant(s)		Sub Class	Filing Date If Appropriate	
							<u> </u>	<u> </u>	ļ	
F	0.45		Dublished			ISHED APPLICATION DOCUMENTS	Class	Sub	F:::	la a Data
Exam Initials	Cite U.S. Published No. Application No.		Publishe Date	a r	lame of Patentee(s) or Applicant(s)	Class	Class	Filing Date If Appropriate		
		<u> </u>					<u> </u>	<u> </u>		
					FOR	EIGN PATENT DOCUMENTS				
Exam Initials	Cite No.	Foreig Office	n Patent D Number		Nam	e of Patentee(s) or Applicant(s)	Date of Trans Publication Yes		slation No	
		wo	2004/007531 A2			LIS PHARMACEUTICALS, INC.;				
	B4					DANA-FARBER CANCER INSTITUTE, INC.; BETH ISRAEL DEACONESS MED. CENTER		01/22/04		
	B5	WO 2004/045557 A2			ARQULE, INC.		06/03/04			
	<u>. </u>						.l		·	
			0	THER PRIOR	ART	- NON PATENT LITERATURE DOCUM	ENTS			
Exam Initials	Cite No. Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.									
						·				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Examiner

Signature

_____, filed _____ continuation-in-part, and divisional applications).